Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology

Kusatsu/Shiga, Japan — May 23, 2017– Takara Bio Inc. announces that HF10 US Phase II clinical trial data will be presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (June 2-6, 2017, Chicago, Illinois, U.S.)
【Outline of presentation】

Name of conference ASCO(American Society of Clinical Oncology) Annual Meeting 2017
Place McCormick Place (Chicago, Illinois, U.S.)
Date June 3
13:15-16:45(Poster session)
16:45-18:00(Poster discussion session)
Title Final results of Phase II multicenter trial of HF10, a replication-competent HSV-1 Oncolytic Virus, and Ipilimumab combination treatment in patients with stage IIIB, IIIC, or IV unresectable or metastatic melanoma
Summary The final results of Phase II clinical trial for oncolytic virus HF10 in the U.S.

Enrollment: Of 46pts enrolled and treated: 37% IV; 43% with ≥ 1 prior cancer therapy for unresectable/metastatic melanoma.

Safety: Most HF10-related AEs were ≤G2, similar to HF10 monotherapy. No DLTs were reported.

Efficacy: Of the 44 efficacy evaluable pts, BORR at 24 weeks was 41%; disease stability rate was 68%. As of Feb 06, 2017, median PFS was 19 months and median overall survival was 21.8 months.

Conclusions: The combination HF10 and ipilimumab treatment demonstrated a more favorable benefit/risk profile than Ipilimumab alone. It suggests that it would be a potential novel therapeutic approach for metastatic melanoma.

Poster Presentation Click here for the poster


For more information:PR・IR Department, Takara Bio Inc.
E-mail: bio-ir@takara-bio.co.jp

This article is translated from press release in Japanese for your convenience.

Forward-Looking Statements
Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors’ prices and product strategies, decline in selling power of the Company’s existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

return to top